Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half ...
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback